US 11,718,679 B2
CD137 antibodies and PD-1 antagonists and uses thereof
Ugur Eskiocak, Somerville, MA (US); and Robert V. Tighe, III, North Reading, MA (US)
Assigned to Compass Therapeutics LLC, Cambridge, MA (US)
Appl. No. 16/760,600
Filed by Compass Therapeutics LLC, Brighton, MA (US)
PCT Filed Oct. 31, 2018, PCT No. PCT/US2018/058451
§ 371(c)(1), (2) Date Apr. 30, 2020,
PCT Pub. No. WO2019/089753, PCT Pub. Date May 9, 2019.
Claims priority of provisional application 62/579,337, filed on Oct. 31, 2017.
Prior Publication US 2021/0221902 A1, Jul. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/001111 (2018.08); A61K 39/001117 (2018.08); A61P 35/00 (2018.01); A61K 2039/507 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] 28 Claims
OG exemplary drawing
 
1. A method for treating cancer in a subject, the method comprising: administering to the subject an effective amount of:
(i) an isolated agonistic monoclonal antibody that specifically binds to human CD137 with an affinity (KD) of about 30-100 nM, or that binds to an epitope on human CD137 comprising K114 of SEQ ID NO: 3, or both, or an antigen-binding fragment thereof; and
(ii) a PD-1 antagonist,
wherein the agonistic monoclonal antibody or antigen-binding fragment thereof is administered to the subject prior to administration of the PD-1 antagonist, thereby treating the subject, and
wherein the isolated agonistic monoclonal antibody or antigen-binding fragment thereof comprises heavy and light chain CDRs comprising heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively.